This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The upcoming Medicare Prescription Payment Plan (M3P), set to launch in January 2025, marks a significant shift in Medicare’s approach to prescriptiondrug coverage. How M3P Payments are Calculated Under M3P, payments are calculated using a formula defined by the Centers for Medicare and Medicaid Services (CMS).
The upcoming Medicare Prescription Payment Plan (M3P), set to launch in January 2025, marks a significant shift in Medicare’s approach to prescriptiondrug coverage. How M3P Payments are Calculated Under M3P, payments are calculated using a formula defined by the Centers for Medicare and Medicaid Services (CMS).
Following the BLS report on the CPI for June 2024, PwC published their new annual report from PwC titled Behind the Numbers 2025 tells us that commercial health care spending is expected to grow some 8.0% (Motor vehicle insurance costs grew a whopping 19.5% in the report, FYI). for Group plans and 7.5% and 7.0%, respectively.
All rebate payments will be deposited into the Medicare PrescriptionDrug Account in the Federal Supplementary Medical Insurance Trust Fund. The thirty-day public comment period ends on March 11, 2023. Part B inflation rebates are measured on a quarterly basis, with the first quarter having begun on January 1, 2023.
Never before have we been able to negotiate prescriptiondrugprices. ” The bill extends the enhanced subsidies, which will expire this year if they are not continued, through 2025. Another big saver for Americans enrolled in Medicare would be a $2,000 cap on out-of-pocket drug costs, which would begin in 2025.
New president tapped to lead major hospital system in Denver area New president to lead opening of $650M hospital in Wheat Ridge Telehealth program offers support to forensic nurses Colorado Medicaid program settles lawsuit over lack of mental health care for children Colorado is trying to cut prescriptiondrugprices.
Health Policy Commission still missing key document in Steward sale to Optum Local obesity drug developer lands deal worth up to $600M with Novo Nordisk Mass. Health Policy Commission still missing key document in Steward sale to Optum Local obesity drug developer lands deal worth up to $600M with Novo Nordisk Mass.
NATIONAL 5 Stark law issues physicians are closely watching Anti-monopoly advocates urge FTC to block McKesson, Cardinal Health’s big-ticket oncology acquisitions Biden administration doles out $68.5M to resolve fraudulent lab testing allegations Lilly to invest another $4.5B to make breast cancer treatments safer St.
in Medicare fraud settlement 10 behavioral health policy changes taking effect in 2025 An uncertain era for Stark law: 12 updates in 2024 CMS launches campaign to support nursing home staffing rule CMS taps 4 states for behavioral innovation model: 5 things to know Epic files to dismiss antitrust lawsuit Healthcare company to pay $15.2
elections, on probably policy and market impacts that we can expect in 2025 and beyond. consumer dissatisfaction with drugprices — across political party identification. insured consumers’ perspectives on prescriptiondrugpricing and the role of PBMs (pharmacy benefit managers).
We organize all of the trending information in your field so you don't have to. Join 26,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content